Daphne Koller, CEO and Founder at insitro delivers a Keynote presentation at WiDS Stanford University on March 2, 2020:
Modern medicine has given us effective tools to treat some of the most significant and burdensome diseases. At the same time, it is becoming consistently more challenging to develop new therapeutics: clinical trial success rates hover around the mid-single-digit range; the pre-tax R&D cost to develop a new drug (once failures are incorporated) is estimated to be greater than $2.5B; and the rate of return on drug development investment has been decreasing linearly year by year, and some analyses estimate that it will hit 0% before 2020. A key contributor to this trend is that the drug development process involves multiple steps, each of which involves a complex and protracted experiment that often fails.
We believe that, for many of these phases, it is possible to develop machine learning models to help predict the outcome of these experiments, and that those models, while inevitably imperfect, can outperform predictions based on traditional heuristics. The key will be to train powerful ML techniques on sufficient amounts of high-quality, relevant data.
To achieve this goal, we are bringing together cutting edge methods in functional genomics and lab automation to build a bio-data factory that can produce relevant biological data at scale, allowing us to create large, high-quality datasets that enable the development of novel ML models. Our first goal is to engineer in vitro models of human disease that, via the use of appropriate ML models, are able to provide good predictions regarding the effect of interventions on human clinical phenotypes. Our ultimate goal is to develop a new approach to drug development that uses high-quality data and ML models to design novel, safe, and effective therapies that help more people, faster, and at a lower cost.
Learn more: widsconference.org
Forgot Password
Almost there!
We just sent you a verification email. Please verify your account to gain access to
Women In Data Science (WiDS) 2020 | Stanford, CA. If you don’t think you received an email check your
spam folder.
Sign in to Women In Data Science (WiDS) 2020 | Stanford, CA.
In order to sign in, enter the email address you used to registered for the event. Once completed, you will receive an email with a verification link. Open this link to automatically sign into the site.
Register For Women In Data Science (WiDS) 2020 | Stanford, CA
Please fill out the information below. You will recieve an email with a verification link confirming your registration. Click the link to automatically sign into the site.
You’re almost there!
We just sent you a verification email. Please click the verification button in the email. Once your email address is verified, you will have full access to all event content for Women In Data Science (WiDS) 2020 | Stanford, CA.
I want my badge and interests to be visible to all attendees.
Checking this box will display your presense on the attendees list, view your profile and allow other attendees to contact you via 1-1 chat. Read the Privacy Policy. At any time, you can choose to disable this preference.
Select your Interests!
add
Upload your photo
Uploading..
OR
Connect via Twitter
Connect via Linkedin
EDIT PASSWORD
Share
Forgot Password
Almost there!
We just sent you a verification email. Please verify your account to gain access to
Women In Data Science (WiDS) 2020 | Stanford, CA. If you don’t think you received an email check your
spam folder.
Sign in to Women In Data Science (WiDS) 2020 | Stanford, CA.
In order to sign in, enter the email address you used to registered for the event. Once completed, you will receive an email with a verification link. Open this link to automatically sign into the site.
Sign in to gain access to Women In Data Science (WiDS) 2020 | Stanford, CA
Please sign in with LinkedIn to continue to Women In Data Science (WiDS) 2020 | Stanford, CA. Signing in with LinkedIn ensures a professional environment.
Are you sure you want to remove access rights for this user?
Details
Manage Access
email address
Community Invitation
Machine Learning: A New Approach to Drug Discovery | Daphne Koller | WiDS 2020
Daphne Koller, CEO and Founder at insitro delivers a Keynote presentation at WiDS Stanford University on March 2, 2020:
Modern medicine has given us effective tools to treat some of the most significant and burdensome diseases. At the same time, it is becoming consistently more challenging to develop new therapeutics: clinical trial success rates hover around the mid-single-digit range; the pre-tax R&D cost to develop a new drug (once failures are incorporated) is estimated to be greater than $2.5B; and the rate of return on drug development investment has been decreasing linearly year by year, and some analyses estimate that it will hit 0% before 2020. A key contributor to this trend is that the drug development process involves multiple steps, each of which involves a complex and protracted experiment that often fails.
We believe that, for many of these phases, it is possible to develop machine learning models to help predict the outcome of these experiments, and that those models, while inevitably imperfect, can outperform predictions based on traditional heuristics. The key will be to train powerful ML techniques on sufficient amounts of high-quality, relevant data.
To achieve this goal, we are bringing together cutting edge methods in functional genomics and lab automation to build a bio-data factory that can produce relevant biological data at scale, allowing us to create large, high-quality datasets that enable the development of novel ML models. Our first goal is to engineer in vitro models of human disease that, via the use of appropriate ML models, are able to provide good predictions regarding the effect of interventions on human clinical phenotypes. Our ultimate goal is to develop a new approach to drug development that uses high-quality data and ML models to design novel, safe, and effective therapies that help more people, faster, and at a lower cost.
Learn more: widsconference.org
